Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Jian Zhang1, Zhen Jia1, Joseph Ragaz2, Ying-Jian Zhang3, Min Zhou3, Yong-Ping Zhang3, Gang Li4, Bi-Yun Wang1, Zhong-Hua Wang1 and Xi-Chun Hu1*

Author affiliations

1 Department of Medical Oncology, Department of Oncology, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China

2 Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada

3 Department of Nuclear Medicine, Department of Oncology, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China

4 Department of Medical Oncology, Fudan University Shanghai Cancer Center Minhang Branch, Fudan University, Shanghai, China

For all author emails, please log on.

Citation and License

BMC Cancer 2013, 13:42  doi:10.1186/1471-2407-13-42

Published: 31 January 2013

Abstract

Background

Whether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still unknown and need to be investigated.

Methods

305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively followed up.

Results

In total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model.

Conclusions

SUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype, does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic disease of luminal subtype.

Keywords:
Metastatic breast cancer; Luminal subtype; PET/CT; SUVmax; Prognosis